Mission: Make CAR-T work in solid tumors.
The Challenges We're Addressing.
CAR-T transformed the treatment of blood cancers. The field has spent years working out why it hasn't repeated that in solid tumors. The reasons fall into three buckets, and that separation is why progress has been slow.
Toxicity
On-target, off-tumor toxicity remains a major challenge because solid-tumor targets are rarely tumor-exclusive; CAR-T cells potent enough to eliminate tumors may also damage normal tissues expressing the same antigen. In addition, cytokine release syndrome (CRS) may become more pronounced as the magnitude of immune-cell activation increases.
Tumor Microenvironment
The extracellular matrix and immunosuppressive tumor microenvironment can impair CAR-T infiltration, activation, persistence, and antitumor function.
Exhaustion
Tonic and chronic antigen signaling can drive CAR-T cells into an exhausted state, progressively reducing their proliferative capacity, cytotoxic activity, and persistence. In solid tumors, this loss of function limits both the strength and duration of the therapeutic response.
The Trade-Off
Every lever that raises efficacy — more cells, tighter-binding receptors, added payloads — widens the safety and durability problems in the same motion. Fixing one at the expense of the others is not progress, which is why the solution has to address all three at once.
NeXell Solution: All-in-One Platform
NeXell's AI-driven platform integrates two layers of intelligence directly into the CAR system, in a single ultra-compact regulatory module of less than 600 base pairs — an all-in-one, CAR-agnostic approach, designed to improve safety, efficacy and durability simultaneously rather than trading one against another.
NeXell Resolves the Safety-Efficacy Trade-Off
The dial above is what conventional CAR-T looks like: push potency too high, and risks to safety and durability can rise with it. NeXell breaks this tradeoff by dynamically tuning CAR-T activity, preserving potency when needed while protecting safety and durability.
Where It Has Been Shown
Validated in FDA-approved CAR constructs in blood malignancies, and across multiple solid tumor indications — evidence that it travels, not a single result.
NeXell Design Engine:
Data Driven and AI-Guided
NeXell's pipeline is data-driven and AI-guided. Candidates are generated computationally from large biological datasets and machine learning–guided design, then prioritized against defined criteria before anything reaches the bench.
Every experimental result feeds back into the design rules, so the engine improves as it runs — including from the candidates that don't work.
Working with NeXell
Three routes to value — run in parallel